Fusion protein having enhanced in vivo erythropoietin activity
AssigneeCheil Jedang Corporation
InventorsDong-eok Lee, Myung-suk Oh, Ki-wan Kim, Bo-sup Chung, Ji-sook Park
Life of this patent
Estimating the term…
Abstract
Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.
Claims12
A fusion protein comprising human erythropoietin (EPO) having a carboxy terminal and a mutant linked to the carboxy terminal, said mutant being a carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit with one to four amino acid substitutions in the CTP fragment.
Dependencies are inferred from the claim text.